Tout DSpace

Parcourir par sujet "triple negative breast cancer"

Voici les éléments 1-5 de 5

    • Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes 

      Kotoula V., Karavasilis V., Zagouri F., Kouvatseas G., Giannoulatou E., Gogas H., Lakis S., Pentheroudakis G., Bobos M., Papadopoulou K., Tsolaki E., Pectasides D., Lazaridis G., Koutras A., Aravantinos G., Christodoulou C., Papakostas P., Markopoulos C., Zografos G., Papandreou C., Fountzilas G. (2016)
      The purpose of this study is to investigate whether the outcome of breast cancer (BC) patients treated with adjuvant chemotherapy is affected by co-mutated TP53 and PIK3CA according to stromal tumor-infiltrating lymphocytes ...

    • The fate of BRCA1-related germline mutations in triple-negative breast tumors 

      Kotoula V., Fostira F., Papadopoulou K., Apostolou P., Tsolaki E., Lazaridis G., Manoussou K., Zagouri F., Pectasides D., Vlachos I., Tikas I., Lakis S., Konstantopoulou I., Pentheroudakis G., Gogas H., Papakostas P., Christodoulou C., Bafaloukos D., Razis E., Karavasilis V., Bamias C., Yannoukakos D., Fountzilas G. (2017)
      The preservation of pathogenic BRCA1/2 germline mutations in tumor tissues is usually not questioned, while it remains unknown whether these interact with somatic genotypes for patient outcome. Herein we compared germline ...

    • Potential role of immunotherapy for advanced breast cancer 

      De Mello R.A., Amaral G.A., Tajima C.C., Tadokoro H., Iavelberg J., Simonetti D., Tolia M., Silva J.A. (2021)
      [No abstract available]

    • TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting 

      Fountzilas G., Giannoulatou E., Alexopoulou Z., Zagouri F., Timotheadou E., Papadopoulou K., Lakis S., Bobos M., Poulios C., Sotiropoulou M., Lyberopoulou A., Gogas H., Pentheroudakis G., Pectasides D., Koutras A., Christodoulou C., Papandreou C., Samantas E., Papakostas P., Kosmidis P., Bafaloukos D., Karanikiotis C., Dimopoulos M.-A., Kotoula V. (2016)
      Background: We investigated the impact of PIK3CA and TP53 mutations and p53 protein status on the outcome of patients who had been treated with adjuvant anthracycline-taxane chemotherapy within clinical trials in the pre- ...

    • Tumor infiltrating lymphocytes affect the outcome of patients with operable triple-negative breast cancer in combination with mutated amino acid classes 

      Kotoula V., Lakis S., Vlachos I.S., Giannoulatou E., Zagouri F., Alexopoulou Z., Gogas H., Pectasides D., Aravantinos G., Efstratiou I., Pentheroudakis G., Papadopoulou K., Chatzopoulos K., Papakostas P., Sotiropoulou M., Nicolaou I., Razis E., Psyrri A., Kosmidis P., Papadimitriou C., Fountzilas G. (2016)
      Background: Stromal tumor infiltrating lymphocytes (TILs) density is an outcome predictor in triple-negative breast cancer (TNBC). Herein we asked whether TILs are related to coding mutation load and to the chemical class ...